ASTRAZEN · AstraZeneca Pharma India Ltd · Biotechnology & Drugs
ASTRAZEN · AstraZeneca Pharma India Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
36.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹683 Cr
Revenue YoY
PAT YoY
-32.1%
Operating margin
Revenue, last 5 quarters
Source: Yahoo Finance, as of 30 Jun 2026
P/E (TTM)
P/B
18
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
+0.6%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ASTRAZEN (this stock) | 92.8 | 18 | +7.0% | +21.5% | 0.13 | +0.6% |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
falling 1q
MF
6.01% (+0.35pp)
rising 3q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- lowthehindubusinessline.com· 20 Oct 2026, 04:32 pmAZ set to move its registered office to Maharashtra, from Karnataka
- mediumbusiness-standard.com· 10 Aug 2026, 02:50 pmUpper Circuit Share: Kwality Pharma, Aarti Pharmalabs, Universal Cables hit 20% upper circuits
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAstraZeneca Pharma India Limited reported a 33% year-on-year revenue growth to ₹22,756 million in FY2025-26, driven by its science-led portfolio and disciplined execution. The company ceased operations at its Bengaluru manufacturing facility, surrendering the licence voluntarily. Key audit matters include contingent liabilities related to tax and regulatory disputes, with ₹1,692.5 million in tax demands and ₹1,573.9 million in regulatory disputes pending adjudication. The company also faces restructuring costs from the Bengaluru facility shutdown, with ₹509.1 million paid in severance and a ₹139.7 million provision remaining. No regulatory actions or defaults were noted, and the company maintains a going concern basis.
- 33% YoY revenue growth to ₹22,756 million in FY2025-26.
- Voluntary surrender of Bengaluru manufacturing licence, with ₹509.1 million severance paid and ₹139.7 million provision remaining.
- Contingent liabilities of ₹1,692.5 million (tax) and ₹1,573.9 million (regulatory) pending adjudication.
- No defaults, regulatory penalties, or liquidity issues reported.
- Audit highlights key risks around tax disputes and restructuring costs.
Key takeaway: AstraZeneca India delivered strong revenue growth but faces unresolved contingent liabilities and restructuring costs, necessitating monitoring of tax and regulatory outcomes.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
3 occurrencesRecent (last 12 months)
The excerpt mentions reviewing reasons for substantial defaults in payments to depositors, debenture holders, and shareholders.
Older (3+ years ago)
AstraZeneca Pharma India Limited has undisputed statutory dues deposited as of March 31, 2023, but there are disputes over income tax and value added tax (VAT) with specific amounts and authorities listed, indicating potential defaults or covenant breaches.
The excerpt mentions reviewing the reasons for substantial defaults in the payment to the depositors, debenture holders.
Routine disclosures
Contingent Liability
5 occurrencesRecent (last 12 months)
AstraZeneca Pharma India Limited has contingent liabilities related to tax and regulatory matters amounting to ₹1,212.3 and a regulatory demand of ₹1,573.9 as of March 31, 2026.
Earlier (1-3 years ago)
AstraZeneca Pharma India Limited has contingent liabilities of ₹1,573.9 million related to pending tax and regulatory matters as of March 31, 2025.
The auditor mentions contingent liabilities related to direct, indirect tax and regulatory matters, which are disclosed in Notes 19 and 20 of the financial statements.
Older (3+ years ago)
The company has contingent liabilities of ₹1,302.5 million along with a regulatory demand of ₹1,573.9 million related to tax and regulatory disputes, which are significant to the financial statements.
The company has pending direct and indirect tax and regulatory matters, including transfer pricing adjustments with overseas group companies and disallowance of certain expenses, which are classified as contingent liabilities in the financial statements.
Related-Party Transaction
4 occurrencesEarlier (1-3 years ago)
The Company has entered into transactions with related parties in compliance with Sections 177 and 188 of the Act. The details of related party transactions have been disclosed in the financial statements as required under Indian Accounting Standard 24.
AstraZeneca Pharma India Limited entered into materially significant related party transactions with AstraZeneca UK Limited and AstraZeneca AB, Sweden for purchase, transfer and receipt of p
Older (3+ years ago)
The company seeks approval for related party transactions with AstraZeneca UK Limited, involving an aggregate value of up to ₹600 crore for purchases, transfers, and services between the 44th and 45th Annual General Meetings.
The company seeks member approval for recurring related-party transactions with AstraZeneca UK Limited, exceeding 10% of turnover annually, under SEBI guidelines requiring annual member approval for such transactions.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.8% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).